News NICE finally recommends Eisai breast cancer drug after rethi... New trial evidence and price cut convinces NICE in reassessment.
News UK aims to cut four years from drug development process NICE, regulator and NHS should work together, according to review.
UK & Europe NICE says Otezla's bargain price offsets lower efficacy Otezla cheap and convenient, but less effective than rivals, says NICE.
News NICE rejects Keytruda in lung cancer, points to price and da... Cancer immunotherapy too expensive.
News Vertex seeks deal after NICE rejects CF drug Orkambi Company in talks with NICE over patient access scheme.
Market Access Consolidating data strategy for global success: Insights fro... At Frontiers Health 2025, Drew McCormick, Head of Data and Analytics at EVERSANA, emphasised a critical truth: data strategy is launch strategy.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
